Open1.710 | Close- |
Vol / Avg.536.603K / 903.003K | Mkt Cap132.182M |
Day Range1.700 - 1.890 | 52 Wk Range0.545 - 2.530 |
BioLine Rx Stock (NASDAQ: BLRX) stock price, news, charts, stock research, profile.
Open1.710 | Close- |
Vol / Avg.536.603K / 903.003K | Mkt Cap132.182M |
Day Range1.700 - 1.890 | 52 Wk Range0.545 - 2.530 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.210 | -0.260 | -0.0500 | ||||
REV | 0 |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.300 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-11-20 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 21.00 |
2023-09-15 | HC Wainwright & Co. | Joseph Pantginis | Maintains | BuyBuy | Raises | 19.00 | 21.00 |
2023-08-31 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 19.00 |
2023-05-25 | Oppenheimer | Mark Breidenbach | Reiterates | Outperform | Maintains | - | 4.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BLRX | BioLine Rx | 7.02% | 132.2M |
OTLK | Outlook Therapeutics | -2.86% | 111.8M |
GRPH | Graphite Bio | -4.85% | 125.3M |
GALT | Galectin Therapeutics | 4.66% | 124.9M |
BRNS | Barinthus Biotherapeutics | -0.16% | 119.2M |
You can purchase shares of BioLine Rx (NASDAQ: BLRX) through any online brokerage.
Other companies in BioLine Rx’s space includes: Outlook Therapeutics (NASDAQ:OTLK), Graphite Bio (NASDAQ:GRPH), Galectin Therapeutics (NASDAQ:GALT), Barinthus Biotherapeutics (NASDAQ:BRNS) and Adaptimmune Therapeutics (NASDAQ:ADAP).
The latest price target for BioLine Rx (NASDAQ: BLRX) was reported by HC Wainwright & Co. on Monday, November 20, 2023. The analyst firm set a price target for 21.00 expecting BLRX to rise to within 12 months (a possible 1047.54% upside). 4 analyst firms have reported ratings in the last year.
The stock price for BioLine Rx (NASDAQ: BLRX) is $1.83 last updated Today at December 8, 2023 at 7:08 PM UTC.
There is no dividend information for BioLine Rx.
BioLine Rx’s Q3 earnings are confirmed for Monday, November 20, 2023.
There is no upcoming split for BioLine Rx.
BioLine Rx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.